Study Data from Denali Therapeutics Inc. Provide New Insights into Science (CD98hc is a target for brain delivery of biotherapeutics).

Předmět:
Zdroj: Drug Week; 9/8/2023, p2756-2756, 1p
Abstrakt: Keywords: Business; Drugs and Therapies; Pharmaceutical Companies; Science EN Business Drugs and Therapies Pharmaceutical Companies Science 2756 2756 1 09/04/23 20230908 NES 230908 2023 SEP 8 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Research findings on science are discussed in a new report. According to news originating from the Denali Therapeutics Inc. by NewsRx correspondents, research stated, "Brain exposure of systemically administered biotherapeutics is highly restricted by the blood-brain barrier (BBB).". [Extracted from the article]
Databáze: Complementary Index